IQ Consortium’s Impact

Founded in 2010 by five companies, the IQ Consortium has grown into a 40-company organization with approximately 1,200 scientists seeking to advance pharmaceutical science and technology for the ultimate benefit of patients, regulators, and the broader research and development community. During the course of IQ’s existence, three key areas have emerged as central to IQ’s efforts to advance its mission and impact pharmaceutical science and regulation. These “impact areas” center on advancing best practices, informing standards and regulation, and facilitating constructive scientific exchange.

By developing best practices, IQ is actively contributing to scientific dialogue, leveraging the collective knowledge of member companies to develop data-driven conclusions and recommendations.

By seeking to inform standards and regulation, IQ is translating its collective knowledge and expertise into meaningful recommendations that may be integrated into influential guidance.

By facilitating constructive scientific exchange, IQ is recognizing its place in this broader community, and the need to collaborate across organizations to ensure that the best possible expertise is leveraged, broader consensus can be reached, and duplication of effort is prevented.

IQ has made significant progress in each of these areas. Since 2010, the Consortium has published nearly 50 publications, submitted more than 40 comments on standards and regulation, and hosted dozens of events. IQ has also formed collaborations with numerous external organizations, held scientific events in conjunction with global regulatory agencies, and engaged several individuals from FDA in Working Groups as invited guests. Beyond this, IQ has become an innovation incubator, and fostered the establishment of several new collaborative efforts, including the Allotrope Foundation, the Enabling Technologies Consortium, the Drug-Induced Liver Injury Initiative, and the Microphysiological Systems Initiative.